An observational study in Choroidal Neovascularization and Mineralocorticoid Excess, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Recruiting at 2 sites in France. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-07-07.
Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Observational
The aim of the study is to find biomarkers in the blood and aqueous humor of patients with type 1 choroidal neovascularization and correlate them with the response to anti-VEGF treatment.
Age-related macular degeneration (AMD) is the most frequent cause of blindness in industrialized countries. Multiple molecular pathways have been implicated in the pathogenesis of choroidal neovascularization (CNV). Currently, the treatment relies on neutralization of VEGF (Vascular Endothelial Growth Factor). However some patients have an incomplete response to anti-VEGF treatment. A recent study suggested the implication of the mineralocorticoid receptor pathway in the formation of CNV.
The study (of investigators) aim is to evaluate the concentation of metabolites of MR pathway in the blood and aqueous humor of patients with CNV and compared them with patients without CNV in order to increase our understanding of CNV pathogenesis and find potential biomarker of response to anti-VEGF treatment.
214 studies on the registry are indexed under Choroidal Neovascularization; 12 are open to participants now.
This study's planned enrollment of 250 is above the median of 79 across 42 observational studies indexed under Choroidal Neovascularization.
Browse Choroidal Neovascularization studies →Institut National de la Santé Et de la Recherche Médicale, France is the lead sponsor of 378 studies on the registry; 81 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Group 1 : patients with type 1 choroidal neovascularization Group 2: patients without choroidal neovascularization before ocular surgery
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients of group 1:
Patients of group 2:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with choroidal neovascularization in the context of age-related macular degeneration or central serous chorioretinopathy
Other: Blood and aqueous humor biomarker of treatment response
Control group : patients without choroidal neovascularization
Other: Blood and aqueous humor biomarker of treatment response
Blood analyses and aqueous humor analysis
biomarker analysis in blood and aqueous humor of patients with neovascularization and controls
Biomarker concentrations (pg/ml) will be evaluated with ELISA (Enzyme Linked ImmunoSorbent Assay).
Time frame: 24 months
biomarker analysis in blood and aqueous humor of patients with neovascularization and controls
Biomarker concentrations (pg/ml) will be evaluated with Mulitplex Biorad.
Time frame: 24 months
biomarkers and treatment response
Correlation between biomarker level and the response to anti-VEGF treatment
Time frame: 24 months
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Choroidal Neovascularization →
Institut National de la Santé Et de la Recherche Médicale, France →